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TECHNICAL NOTE
An ELISA for the detection of type IV collagen in human
urine—Application to patients with glomerulonephritis
KIERON L. DoNov, GERALD A. COLES, and Jow' D. WILLIAMS
Institute of Nephrology, Royal Infir,naiy, Cardiff Wales, United Kingdom
Type IV collagen is the principal component of glomerular
basement membrane (GBM) [1]. It renders structural support,
provides a matrix for cell adhesion [2,3] and contributes to glomeru-
lar permselectivity for macromolecules [3]. Normally there is a
constant remodelling of GBM, as a result of balanced degradation
by a number of glomerular cell derived proteinases, and synthesis,
principally by glomerular epithelial cells [4]. Alteration of the
integrity of the glomerular filtration barrier is widely believed to
be the cause of the proteinuria and haematuria associated with a
number of different glomerulonephritides. In vitro studies of
GBM degradation quantified the release of hydroxyproline rich,
soluble type IV collagen-derived peptides as a marker for GBM
damage, and have demonstrated that small, soluble peptide
fragments are released from the insoluble GBM by the action of
proteinases [5—8]. A number of in vivo studies have identified
glomerular basement antigens in the urine of normal animals
which increase in concentration during acute experimental ne-
phritis [9]. Analysis of the urine of patients with rapidly progres-
sive glomerulonephritis (RPGN) showed that immunoreactive
GBM antigens were detectable in much higher concentration than
in normal urine [10]. This study, however, did not identify or
accurately quantify specific antigens but did attempt to define
glomerular damage more specifically than did proteinuria. Other
studies using immunoassays for both type IV collagen and its NC1
region in patients with diabetic nephropathy have yielded conflict-
ing data [11—13]. An investigation in patients with active nephritis,
however, has reported elevated urinary IV collagen [14}.
In the present study the development of a competition ELISA
for human type IV collagen in urine is detailed. Analysis of the
urine of patients with a number of differing glomerulonephritides,
including RPGN, and diabetic nephropathy is compared with
normals. In addition the effects of conventional therapy on the
excretion of type IV collagen in patients with RPGN is examined.
Methods
Human type IV and type I collagen
Human type IV and type I collagen, prepared from placenta by
pepsin digestion, were purchased from Collaborative Biomedical
Products (Becton Dickinson Labware, Bedford, Massachusetts,
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USA). The products were verified as > 95% pure by SDS-PAGE
and supplied as a 1 mg/ml solution in 10 m acetic acid. The
collagens were diluted in Dulbecco's phosphate buffered saline
pH 7.3 (PBS) to appropriate concentrations and stored at —70°C
for up to six months.
Antibodies
Rabbit anti-human type IV collagen antibody (PS 44) was
obtained from Monosan (Bradsure Biologicals, Market Harbor-
ough, UK). The antibody was raised in rabbits immunized with
pure human type IV collagen and adsorbed with normal human
serum proteins and human collagens types I, II, III and V.
Antiserum was diluted in PBS, aliquoted and stored at —20°C
until used. Western blot analysis of intact type IV collagen dem-
onstrated that the antibody reacted principally with the al (150
kDa) and a2 (140 kDa) collagen chains.
Affinity isolated alkaline phosphatase conjugated, goat anti-
rabbit IgG (whole molecule) (A-3812), which had been adsorbed
with human serum proteins, was obtained from Sigma (Poole,
UK) and stored at 4°C.
Urine sample preparation and storage
Clean catch urine specimens were obtained from normal vol-
unteers, patients with biopsy-proven chronic glomerular diseases
and normal renal function; specimens were also taken from
patients with non-immunologic renal disease and normal renal
function and patients with RPGN. After collection, samples were
mixed with EDTA (10 mM) and 1 ml aliquots were stored at
— 70°C until analyzed. Prior to analysis samples were defrosted at
room temperature and centrifuged at 12000 g for three minutes in
a Beckman Microfuge (Beckman Instruments mc, Fullerton,
California, USA) to remove crystalline debris.
Urine creatinine and protein assays
Urine samples were analyzed for creatinine using an established
routine assay within the Biochemistry Department at the Royal
Infirmary. Total urine protein was analyzed after trichloroacetic
acid precipitation, re-dissolving the precipitate in 0.1 M NaOH,
and analysis of the solution by the method of Lowry using bovine
serum albumin (BSA) as the standard.
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ELISA
The fully developed ELISA was performed as follows.
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Each well of a polystyrene microtiter plate (Immulon 4, Dy-
natech Laboratories, Chantilly, Virginia, USA) was coated over-
night at 4°C with 100 1.d of type IV collagen at a concentration of
100 ng/ml in phosphate buffered saline (pH 7.3). After discarding
the IV collagen coating solution, plates were then blocked for two
hours at room temperature with PBS containing 3% BSA. One
hundred and fifty microliters of pre-prepared standards of type IV
collagen dissolved in PBS or samples of neat urine were mixed
with an equal volume of rabbit anti-human type IV collagen
diluted 1:250 in PBS containing 0.1% Tween 20 (vol/vol) and
0.2% BSA (wt/vol) (PBST/BSA) and incubated overnight at 4°C.
Pre-coated, blocked plates were washed four times with PBS
containing 0.1% Tween 20 (PBST) and 100 1 of each sample or
standard, after incubation with anti-type IV collagen antibody,
was added in duplicate. Plates were then incubated at room
temperature for one hour. After four further washes 100 d of
alkaline phosphatase labelled goat anti-rabbit IgG diluted 1:1000
in PBSTIBSA was added and the plates incubated for an hour at
room temperature. Plates were washed for a final time and 100 j.d
of the substrate chromophore, [para-nitro-phenyl-phosphate
(pNPP; Sigma) 1 mg/mi in 10% (wt/vol) diethanolamine buffer
containing 0.5 mtvi MgCl2, pH 9.81, was added and color devel-
oped for 60 minutes at 37°C. Absorbance was read at 410 nM on
a plate reader (MRS000/340, Dynatech Laboratories mc, Billing-
shurst, UK). Results were calculated as the % inhibition of
anti-type IV collagen activity by dividing the sample and standard
OD value by that of the maximum OD obtained using anti-type IV
collagen pre-incubated with PBS alone. Standard curves were
included on each assay plate covering the range 0.5 to 200 ng/ml
type IV collagen.
Calculation of type IV collagen concentrations
Standard curves of % inhibition vs log concentration of type IV
collagen were calculated using the Statview program on an Apple
Macintosh LC computer. Unknown values were calculated from
the curve fit formula using Microsoft Excel 3.0 software.
Results
Development of the ELISA
Various parameters of the ELISA were examined in order to
produce the most reproducible and sensitive assay.
Optimal IV collagen coating concentration
Initial experiments had shown that optimal binding of IV collagen
to microtiter plates occurred at neutral pH and either at room
temperature for six hours or overnight at 4°C (data not shown),
Coating and incubation steps at 37°C were avoided since type IV
collagen may spontaneously denature at this temperature. Micro-
titer plates were coated with a range of type IV collagen concen-
trations overnight at 4°C. After blocking with 3% BSA for two
hours, 100 d of anti-type IV collagen, diluted 1:500 in PBST/BSA
was added to each well, incubated for 60 minutes at room
temperature, and the plates washed four times with PBST.
Conjugated second antibody (1:1000 in PBST/BSA) was added
and incubated for another hour at room temperature. The plate
was then washed, 100 1.d substrate chromophore was added to
each well, and color developed at 37°C for 60 minutes, Optimal
coating concentration was identified as the lowest submaximal
Dilution of anti-IV collagen
Fig. 2. Curve showing the ability of increasingly dilute anti-type IV collagen
antibody to detect type IV collagen coated onto immunoassay plates at 100
ng/mL A submaximal dilution within the linear portion of the curve was
chosen as optimal (1:500).
concentration which still yielded a strong signal, in this case 100
ng/ml (Fig. 1).
Optimal pre-incubation antibody concentration
Optimal amount of anti-type IV collagen antibody for use in
this competition ELISA was identified as the concentration which
bound submaximally to plates coated with 100 ng/ml of IV
collagen, was on the straight line portion of the curve and yielded
a strong signal. This dilution was 1:500 (Fig. 2).
Optimal incubation and pre-incubation conditions
Binding of anti-type IV collagen was assessed at room temper-
ature for different time periods. Near maximal binding was
achieved after — 60 minutes at room temperature (Fig. 3). Optimal
conditions for pre-incubation were determined by incubating a
standard of 50 ng/ml type IV collagen with anti-type IV collagen
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Fig. 1. Curve showing the optical density (OD) obtained after coating the
immunoassay plates with increasing concentrations of type IV collagen and
detecting it as described in the methods. A submaximal concentration of 100
ng/ml was chosen as optimal.
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for various time periods at room temperature and 4°C and
evaluating % inhibition of the antibody. The optimal time period
was 18 hours at both temperatures (Fig. 4). A pre-incubation
protocol at 4°C for 18 hours was chosen for convenience and
better control of temperature.
Evaluation of assay variability
Type IV collagen standards from 0.5 to 200 ng/ml were pre-
incubated with anti-type IV collagen overnight at 4°C. Inhibition
of antibody activity was calculated as detailed above and curves
plotted on a semi-logarithmic scale (Fig. 5). Intra-assay variability
was assessed by analysis of standards in PBS (10 and 120 ng/ml),
and a urine sample with a known amount of type IV collagen 20
times on the same plate. Inter-assay variability for the standards
and urine were calculated by analysis of results from 10 different
plates. Coefficients of variation are given in Table 1. The detection
limit was defined as the mean blank concentration + 3 standard
deviations which was  1.0 ng/ml.
Cross reactivity
The anti-type IV collagen antibody was tested for cross reac-
tivity in ELISA and Western blot analysis with a number of pure
matrix components including laminin, fibronectin, fibrinogen and
type I collagen in different concentrations. There was no cross
reactivity detectable using laminin, fibronectin or fibrinogen at
concentrations of 1000 nglml. Cross reactivity with type I collagen
was calculated as < 0.1% at 1000 ng/ml and < 1.1% at 150 nglml.
No immunoreactivity with the matrix components was seen in
Western blot analysis.
Recovety and parallelism of urine IV collagen
Normal urine was spiked with 20 and 100 ng/ml type IV
collagen and the recovery of type IV collagen by the ELISA was
determined. Recoveries were 95.5% and 106.2%, respectively. A
sample of normal urine (type IV collagen concentration 48 nglml)
was serially diluted with PBS and the slope of the dilution curve
compared with the standard curve (Fig. 6). The curves were
parallel between dilutions of between neat and 1:8, indicating
good specificity of the antibody. Urine samples were subsequently
analyzed undiluted.
Freeze thaw cycles
Up to six freeze-thaw cycles did not significantly affect the
measured concentration of type IV collagen standards or of urine
samples. In the case of the clinical study samples were thawed and
refrozen only on two occasions.
Analysis of intact and digested type IV collagen
Intact type IV collagen (50 ng!ml) was analyzed before and
during digestion using pure human PMN elastase (1 g) or
bacterial collagenase (Sigma Type VII lOu) at room temperature for
up to 60 minutes. There was a tendency for measured values to fall
with time, probably reflecting increasing digestion of collagen.
Results are shown in Table 2.
Urinalysis of patients with RPGN
Nine patients with RPGN due to anti-GBM disease (N = 3),
ANCA positive vasculitis (N = 3), and of idiopathic etiology
0
125-
C
ci, 100-
00
>L 75.C
C
VC
:3 50-
E
25-
0-
Time, minutes
Fig. 3. The effects of time on the binding of anti-type IV collagen (1:500
dilution) to immunoassay plates coated with type IV collagen (100 nglml) at
room temperature. Near maximal binding (% binding = OD/Max OD X
100) was achieved by 60 minutes.
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Fig. 4. Effects of time and temperature on the inhibition of anti-type IV
collagen antibody activity by 50 ng/ml type IV collagen in the liquid phase.
Inhibition was significantly greater at room temperature at all time points
and maximal inhibition was achieved after 18 hours at both temperatures.
0 = room temperature; * = 4°C.
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Intra-assay (N = 20) Interassay (N = 10)
Sample analysed
Standard (10 ng/ml) 30.55 2.01 (6.58) 30.79 3.52 (11.43)
Standard (120 ng/mI) 69.54 1.11 (1.60) 69.31 1.22 (1.75)
Urine (29 ng/ml) 46.99 5.11 (10.87) 47.89 7.03 (14.68)
(N = 3) were studied. All patients were in acute renal failure at
presentation and required intermittent dialysis and immunosup-
pression and/or plasma exchange to manage their disease. Urine
was collected when possible but all patients eventually became
anuric during their illness. Individual values for urinary type IV
collagen are shown in Figure 7. All but three results were above
the normal range.
Effects of treatment of RPGN on IV collagen concentration
Several patients (N 6) were studied during the course of their
RPGN and the effects of treatment on type IV collagen analyzed.
Most patients displayed markedly elevated type IV collagen
excretion at all sample points; however, no significant effects of
plasmapheresis, or drug immunosuppression were evident. A
representative patient response is shown in Figure 8.
Urinalysis of patients with stable chronic renal disease
Urine was obtained from normal subjects (NORM, N = 19) as
well as patients with IgA nephropathy (IgAN, N = 11), membra-
Incubation
mm
Measured type IV collagen ng/ml
Standard Std ÷ elastase Std + collagenase
0 51.3 50.9 51.6
15 48.8 47.6 48.9
30 50.6 45,8 40.7
45 53.1 40.1 31.3
60 48.9 32.1 16.5
nous nephropathy (MN, N = 14), polycystic kidney disease
(PCKD, N = 10), diabetic nephropathy (DN, N = 9), and mesan-
giocapillary glomerulonephritis (MCGN, N = 6). Plasma creati-
nine concentrations were within the normal range in all patients
during the preceeding 6 to 12 months, thus indicating normal
stable renal function (Table 3). Samples were analysed, as de-
scribed above, for type IV collagen, protein and creatinine. All
type IV collagen values were corrected for renal function by
dividing concentration of type IV collagen (ng/ml) by urine
creatinine (mol/ml) and expressed as ng/j.mol. Normal urinary
type IV collagen was defined as the mean value for normals + 3
standard deviations. Results are displayed in Figure 9. Median
(range) values were: NORM, 1.94 (1.00 to 2.77); IgAN, 2.16 (0.5
to 5.31); MN, 5.98 (1.89 to 312.22); PCKD, 3.10 (1.15 to 7.12);
DN, 4.72 (1.67 to 7.65); MCGN, 2.41 (0.71 to 3.12). Data were
non-parametrically distributed and, therefore, values were com-
pared using the Mann Whitney U test, with P values less than 0.05
considered to be significant. Only the diabetic (P = 0.005) and the
membranous nephropathy groups (P = 0.007) had significantly
elevated type IV collagen in their urine when compared to the
normal controls (Fig. 9). There was no correlation between either
urinary creatinine or protein concentrations and the level of type
IV collagen (data not shown).
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Fig. 6. Parallelism between the buffer diluted standard curve for type IV
collagen and increasingly dilute normal human urine. The curves remained
parallel between neat urine and urine diluted 1:8 in incubation buffer.
Symbols are: (•) urine; (0) = buffer.
Table 2. Analysis of a standard of type IV collagen subjected to
digestion by pure PMN elastase and bacterial collagenase at
room temperature for 60 minutes
0 0.5
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Fig. 5. Standard curve of type IVcollagen inhibition ELISA. Data represent
the mean standard deviation of 6 different standard curves on separate
plates.
Table 1. ELISA precision as determined by both intra- and interassay
variability of repeated measurements of buffer diluted standards and
normal urine
Abbreviation is CV, coefficient of variability. Data are presented as
mean % inhibition SD (CV%).
There was a significant fall in measured type IV collagen with prolonged
incubation using both enzymes.
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Fig. 7. Individual measurements of urinaiy type lv collagen in several
patients with rapidly progressive nephritis (RPGN) of a number of different
etiologies. The shaded area represents the normal range of the type IV
collagen concentration in urine. All patients except patient #4 had
significantly elevated median concentrations as compared to the normal
control population.
Fig. 8. Serial changes in urine volume (U), semm creatinine (•) and
urinaiy type IV collagen (0) in a representative patient with RPGN. Urine
volume declined inexorably along with declining renal function. Interven-
tion with intermittent hemodialysis, plasma exchange and immunosup-
pression with corticosteroids and cyclophosphamide did not alter the type
IV collagen concentration in urine.
Discussion
This study describes the development of a specific competition
ELISA which is capable of detecting type IV collagen in human
Table 3. Renal function and proteinuria in the different patient groups
studied in cross section
Diagnosis N
Plasma creatinine
p.,nol/liter
Proteinuria
mg/liter
Normal 19 84 (64—119) 105 (54—154)
IgAN 9 94 (58—126) 124 (44—1166)
MN 14 87 (66—120) 1081 (46—6169)
MCGN 6 80 (55—93) 1250 (745—3201)
PCKD 10 77 (68—99) 121 (18—190)
DN 9 96 (78—121) 138 (35—598)
The values are medians with range in brackets. There were no signifi-
cant differences between any of the plasma creatinines and only the groups
with MN, DN and MCGN had significantly elevated proteinuria (Mann
Whitney U test P < 0.05).
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Fig. 9. Individual values of urinaty type IV collagen concentrations for
groups of patients with chronic stable nephropathies. The shaded area re-
presents the normal range. * P < 0.01 vs. normal controls.
urine. We have shown that patients with both diabetic nephrop-
athy and those with membranous nephropathy have significantly
elevated type IV collagen concentrations in their urine, when
compared to that of patients with other types of GN and normal
controls. Type IV collagen concentrations were independent of
the degree of proteinuria. In addition, patients with RPGN of a
number of different etiologies had raised type IV collagen in their
urine which appeared to be unaffected by conventional treatment
protocols during the early stages of therapy.
The ELISA described in detail in this study enables the
detection of as little as 1 nglml of type IV collagen in urine. The
concentration of type IV collagen in urine from normal subjects
was well above this detection limit, unlike those seen with another
assay whose sensitivity was close to that of normal urinary values
[12]. The antibody used in the present study was highly specific
showing less than 1% cross reactivity with other basement mem-
brane components and collagen type I. The assay showed repro-
ducible recovery and high specificity in urine and detected type IV
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collagen over a 2 log concentration range. There was no apparent
increase in collagen IV concentration when intact antigen was
digested with either PMN elastase or collagenase indicating that
all epitopes were available for binding. Prolonged and substantial
digestion of the IV collagen resulted in a fall in measured collagen
concentration. The use of this single antibody in a competition
ELISA has advantages over two site assays which require 2
distinct epitopes to be structurally linked on a peptide fragment in
order for it to be detected. A 2 site assay is thus more likely to
underestimate the presence of collagen fragments than a single
antibody system such as the one described. Western blot analysis
of pure type IV collagen using this antibody confirmed that it
recognized both native intact and partially degraded collagen
fragments of molecular weight 70 kDa.
The elevated type IV collagen concentrations seen in the urine
of our patients with RPGN extends data from earlier animal and
human studies [9, 10]. These showed that GBM antigens are
excreted in normal urine, and that levels may rise during acute
ON. In a study of patients with RPON, increased immunoreac-
tivity with GBM components was detectable in the concentrated
urine of thirteen patients [10]. Although the components of GBM
in previous studies were broadly identified as basement mem-
brane glycoproteins, precise concentrations of specific antigens
were not evaluated, and there was no correction for either
non-specific proteinuria or renal function. Many forms of RPGN
and animal experimental glomerulonephritis are characterized by
an intraglomerular influx of inflammatory cells, in particular
neutrophils and macrophages, that coincides with the onset of
proteinuria [15—191. In vitro work on the interaction of these cells
and GBM has shown that GBM type IV collagen can be degraded
into hydroxyproline rich peptides by the combined action of cell
derived proteinases [5—8]. We propose that the increase in urinary
type IV collagen excretion in patients with RPON seen in the
present study probably reflects increased GBM degradation by
such inflammatory cells. It is noteworthy that while conventional
immunosuppression in several of these patients reduced levels of
both ANCA and anti-OBM antibodies (data not shown), there
was no concomitant reduction in type IV collagen excretion,
suggesting that glomerular damage was persistent despite this
evidence of immunosuppression.
The striking and unexpected finding of this study was the
elevated urinary type IV collagen in patients with both membra-
nous and diabetic nephropathy. Both of these conditions are
characterized by the presence of a thickened OBM [3]. In vivo
OBM undergoes constant remodelling by the balanced action of
synthesis of individual components such as laminin, type IV
collagen and proteoglycans principally by resident glomerular
epithelial cells, and their degradation by glomerular cell derived
proteinases such as gelatinase [4]. Thickening of OBM thus
implies either an increase in the synthesis of components, a
relative reduction in their degradation, or both. The present study
indicated that in humans with diabetic nephropathy OBM type IV
collagen degradation, and therefore its synthesis were both in-
creased. Previous human studies have, however, yielded conflict-
ing data. Elevated urinary collagen IV has been detected in
diabetic patients, both with [11, 12] and without nephropathy [13].
In separate studies increased levels were confined to diabetic
patients with incipient nephropathy and elevated albuminuria
[20], Moreover, a two site radioimmunoassay, while demonstrat-
ing elevated serum levels of type IV collagen in diabetics, failed to
detect its presence in their urine [21]. Finally, two separate studies
using an immunoassay for type IV collagen NC1 showed normal
levels for diabetics in one [12] and elevated levels in another [20].
In none of these was there any specific correction for renal
concentration of creatinine or calculation of collagen excretion
rate.
In the present study the other group of patients with a significantly
raised type IV collagen excretion were those with membranous
nephropathy (MN). This disorder is characterized by subepithelial
immune deposits, a thickened GBM, proteinuria and an unpre-
dictable clinical course exemplified by both worsening and im-
proving renal function. Up to 25% of patients with MN may
ultimately progress to end-stage renal failure within 10 years of
presentation [22]. Therapeutic studies have tried to identify more
specific urinary markers of ongoing glomerular inflammation such
as the complement components C5b-9 and C3dg since the degree
of histological glomerular inflammation does not correlate well
with total proteinuria [23, 24]. In our study the finding of high
levels of urinary type IV collagen and the presence of basement
membrane thickening implied abnormally increased GBM synthe-
sis and turnover, which, interestingly, did not correlate with
proteinuria. These data differ from an earlier study which showed
decreased levels of type IV collagen NCI [12] in patients with MN
as compared to normals. These anomalies may be methodological
since the levels detected in the previous study were below the
assay sensitivity in 6 of 13 patients analyzed, and furthermore
there was no correction for renal function. In addition the study
also failed to confirm previously published differences between
diabetic and normal urine type IV collagen levels found using the
same assay [20]. Our data suggest that the measurement of urinary
type IV collagen permits non-invasive evaluation of GBM synthe-
sis/degradation.
Several other groups of patients with stable chronic immuno-
logic glomerulonephritis and a tubulointerstitial non-immune-
mediated control (PCKD), all with normal glomerular filtration
rates and serum creatinine were also evaluated. Although the
group of patients with PCKD were not statistically different from
controls, three out of ten had high levels. It is possible that the
increased tubular damage in these three individuals is reflected by
higher urinary collagen levels.
In summary, we have developed a simple, sensitive, and specific
ELISA that can detect human type IV collagen in urine. Elevated
concentrations were only seen consistently in groups of patients
with either chronic nephropathies associated with thickened
OBM, or with significant acute aggressive ON. We suggest that
this assay may identify a more specific marker of glomerular
injury/GBM damage than does proteinuria and may be of use in
longitudinal studies.
Acknowledgment
KLD was supported by a grant from the Welsh Scheme for the
Development of Health and Social Research (WDSR J1143W36C).
Reprint requests to Kieron L. Donovan, Institute of Nephrology, Royal
Infirmaiy, Newport Roa4 Cardi,j Wales, United Kingdom.
References
1. TIMPL R: Recent advances in the biochemistry of glomerular base-
ment membrane. (Editorial Review) Kidney mt 30:293—298, 1986
Donovan et al: Urina,y type IV collagen in GN 1437
2. Giwrr DS, KLEINMAN HK, MARTIN GR: The role of basement
membranes in vascular development. Anna! NYAcad Sci 588:61—72,
1990
3. WEnER M: Basement Membrane Proteins. Kidney mt 41:620—628,
1992
4. DAVIES M, MARTIN J, THOMAS GJ, LOVETF DH: Proteinases and
glomerular matrix turnover. Kidney mt 41:671—678, 1992
5. DAVIES M, BARRET AJ, Ta..vIs J, SANDERS E, COLES GA: The
degradation of human glomerular basement with purified lysosomal
proteinases: Evidence for the pathogenic role of the polymorphonu-
clear leucocyte in glomerulonephritis. C/in Sci Mo! Med 54:233—240,
1978
6. VISSERS CMM, WINTERBOURN CC, HuNT JS: Degradation of glomer-
ular basement membrane by human neutrophils in vitro. Biochim
BiophysActa 804:154—160, 1984
7. VISSERS CMM, WIGGINS R, PANTONE JC: Comparative ability of
human monocytes and neutrophils to degrade glomerular basement
membrane in vitro. Lab Invest 60:831—838, 1989
8. BROWN PD, ROBINSON GB: In vitro studies of the degradation of
glomerular basement membrane by rabbit neutrophil proteinases at
neutral pH, in Glomerular Basement Membrane, edited by Luaac G,
HUDSON BG, John Libbey, 1985, p 151
9. HUTrUNEN NP, TURNER MW, BARRATF TM: Physicochemical char-
acteristics of glomerular basement membrane antigens in urine.
Kidney mt 16:322—328, 1979
10. SANDERS E, COLES GA, DAVIES M: Lysosomal enzymes in human
urine: Evidence for polymorphonuclear leucocyte proteinase involve-
ment in the pathogenesis of human glomerulonephritis. C/in Sci Mo!
Med 54:667—672, 1978
11. HAYASHI Y, MAKINO H, SHIKATA K, HARAMOTO T, YAMASAKI Y,
KUMAGI I, OTA Z: Increased concentrations of the basement mem-
brane component type IV collagen in the sera and urine of diabetics.
JDiab Compl 5:195—196, 1991
12. TORFFVIT 0, AGARDH CD, Aut P, WIESLANDER J: Urine and serum
levels of the carboxyterminal domain (NC1) of collagen IV in
membranous glomerulonephritis and diabetic nephropathy. Nephron
59: 15—20, 1991
13. HAYASHI Y, MAKINO H, OTA Z: Serum and urinary concentrations of
type IV collagen and laminin as a marker of microangiopathy in
diabetes. Diab Med 9:366—370, 1992
14. KELLER F, SER YL, SCHUPPAN D: Raised concentrations of the
carboxyl terminal propeptide of type IV (basement membrane) pro-
collagen (NC1) in serum and urine of patients with glomerulonephri-
tis. EurJ Clin Invest 22:175—181, 1992
15. JOHNSON Ri, ALPERS CE, PRITZL P, SCHULZE M, BAKER P, PRUCHNO
C, COUSER WG: Platelets mediate neutrophil dependent immune
complex nephritis in the rat. J Clin Invest 82:1225—1235, 1988
16. WEISS SJ: Tissue destruction by neutrophils. N Engi J Med 320:365—
376, 1989
17. SHAN SV, BARICOS WH, BASCI A: Degradation of human glomerular
basement membrane by stimulated neutrophils. J C/in Invest 79:25—31,
1987
18. JOHNSON Ri, COUSER WG, CMI EY, ADLER 5, KLEBANOFF SJ: New
mechanism for glomerular injury. Myeloperoxidase-hydrogen perox-
ide-halide system. J Clin Invest 79:1379—1387, 1987
19. SCHRIJVER G, SCHALKWIJK J, ROBBEN 1CM, ASSMANN KJM, KOENE
RA: Antiglomerular basement membrane nephritis in beige mice. J
Exp Med 169:1435—1448, 1989
20. TORFFVIT 0, AGARDH CD, CEDERHOLM B, WIESLANDER J: A new
enzyme linked immunosorbent assay for urine and serum concentra-
tions of the carboxyterminal domain (NC1) of collagen IV-application
to type 1 (insulin dependent) diabetes. Scand J Clin Lab Invest 49:z431—
439, 1989
21. MATSUMOTO E, MATSUMOTO G, O0SHIMA A, KIKUOKA H, BESSFI0 H,
MIYAMURA K, NANJO K: Serum type IV collagen concentrations in
diabetic patients with microangiopathy as determined by enzyme
immunoassay with monoclonal antibodies. Diabetes 39:885—890, 1990
22. CArrlw.4 DC, PEI Y, GREENWOOD C: Predicting progression in
membranous glomerulonephritis. Nephrol Dial Transplant 7(Suppl 1):
z48—52, 1992
23. COUPES BM, KON SP, BRENCHLEY PE, SHORT CD, MALLICK NP: The
temporal relationship between urinary C5b-9 and C3dg and clinical
parameters in human membranous nephropathy. Nephrol Dial Trans-
plant 8:397—401, 1993
24. BRENCHLEY PE, COUPES B, SHORT CD, O'DONOGHUIt DJ, BALLARDIE
FW, MALLICK NP: Urinary C3dg and C5b-9 indicate active immune
disease in human membranous nephropathy. Kidney mt 41:933—937,
1992
